Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bisphosphonates for breast cancer.

N Pavlakis1, Rl Schmidt, M Stockler

  • 1Department of Medical Oncology (Faculty of Medicine), Royal North Shore Hospital (University of Sydney), Pacific Highway, St Leonards, NSW, Australia, 2065. pavlakis@med.usyd.edu.au

The Cochrane Database of Systematic Reviews
|July 22, 2005
PubMed
Summary

Bisphosphonates significantly reduce skeletal events in women with advanced breast cancer and bone metastases. While they may improve bone pain and quality of life, their effect on survival remains uncertain, and effectiveness in early breast cancer requires further research.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX study.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Single-centre experience with peptide receptor radionuclide therapy for neuroendocrine tumours (NETs): results using a theranostic molecular imaging-guided approach.

Journal of cancer research and clinical oncology·2023
Same author

Cost of treating metastatic colorectal cancer: a systematic review.

Public health·2022
Same author

Defining the rate of nutritional and metabolic derangements after pancreatic resection.

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]·2022
Same author

Impact of COVID-19 on cancer service delivery: a follow-up international survey of oncology clinicians.

ESMO open·2021
Same author

Oral THC:CBD cannabis extract for refractory chemotherapy-induced nausea and vomiting: a randomised, placebo-controlled, phase II crossover trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2020

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • Bone metastases are common in breast cancer, causing significant morbidity and mortality.
  • Bisphosphonates inhibit osteoclast activity and are used for hypercalcemia and skeletal events.
  • Previous studies have explored bisphosphonates' role in breast cancer treatment.

Purpose of the Study:

  • To evaluate the impact of bisphosphonates on skeletal events in breast cancer patients.
  • To assess effects on bone pain, quality of life, and survival in early and advanced breast cancer.
  • To compare different bisphosphonates and administration routes (oral vs. intravenous).

Main Methods:

  • Systematic review and meta-analysis of 21 randomized controlled trials.
  • Included studies compared bisphosphonates with placebo or no bisphosphonate treatment.

Related Experiment Videos

  • Data extraction focused on skeletal events, bone pain, quality of life, and survival.

    • Main Results:

    • Bisphosphonates reduced the risk of skeletal events by 17% in advanced breast cancer with bone metastases.
    • Intravenous bisphosphonates showed a slight advantage over oral formulations.
    • Zolendronate demonstrated significant risk reduction for skeletal events; improvements in bone pain and quality of life were noted, but survival benefits were not consistently observed.

    Conclusions:

    • Bisphosphonates are effective in reducing skeletal events and improving time to skeletal events in advanced breast cancer with bone metastases.
    • Potential benefits include reduced bone pain and improved quality of life.
    • Efficacy in early breast cancer and optimal treatment duration require further investigation.